Tyra Biosciences, Inc.: research and development expense
Research and development expense for Tyra Biosciences, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Tyra Biosciences, Inc. financial histories
What this measure means
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
Exact concept: us-gaap:ResearchAndDevelopmentExpense. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2020-01-01 to 2025-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | 102,928,000 | USD | 2026-03-02 | 10-K · 0001193125-26-085490 |
| 2024-01-01 | 2024-12-31 | 80,077,000 | USD | 2026-03-02 | 10-K · 0001193125-26-085490 |
| 2023-01-01 | 2023-12-31 | 62,518,000 | USD | 2025-03-27 | 10-K · 0000950170-25-046124 |
| 2022-01-01 | 2022-12-31 | 43,008,000 | USD | 2024-03-19 | 10-K · 0000950170-24-033461 |
| 2021-01-01 | 2021-12-31 | 20,636,000 | USD | 2023-03-22 | 10-K · 0000950170-23-009181 |
| 2020-01-01 | 2020-12-31 | 7,203,000 | USD | 2022-03-03 | 10-K · 0000950170-22-002814 |
Related financial histories
- Tyra Biosciences, Inc.: total assets
- Tyra Biosciences, Inc.: total liabilities
- Tyra Biosciences, Inc.: stockholders equity
- Tyra Biosciences, Inc.: cash and cash equivalents
- Tyra Biosciences, Inc.: net income or loss
- Tyra Biosciences, Inc.: operating cash flow
- Tyra Biosciences, Inc.: capital expenditure payments
- Tyra Biosciences, Inc.: financing cash flow
- Tyra Biosciences, Inc.: investing cash flow
- Tyra Biosciences, Inc.: retained earnings or deficit
- Tyra Biosciences, Inc.: basic weighted-average shares
- Tyra Biosciences, Inc.: diluted weighted-average shares
- Tyra Biosciences, Inc.: basic earnings per share
- Tyra Biosciences, Inc.: diluted earnings per share
- Tyra Biosciences, Inc.: income tax expense or benefit
- Tyra Biosciences, Inc.: net property, plant and equipment
- Tyra Biosciences, Inc.: share-based compensation expense
- Tyra Biosciences, Inc.: operating income or loss
- Tyra Biosciences, Inc.: current assets
- Tyra Biosciences, Inc.: current liabilities
- Tyra Biosciences, Inc.: current accounts payable
- Tyra Biosciences, Inc.: operating expenses
Inspect the source
- Entity
- Tyra Biosciences, Inc. / CIK 0001863127
- Captured
- 2026-09-21T17:31:58.165Z
- SEC response SHA-256
5e0cf474842e98a04459db8fd4915eaf5e7be7970e91ea2a5552864e1ab50f8c
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001863127.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))